Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
Narrowing drug patents that claim more than they disclose would open space for rival innovators rather than generics.
- Why it matters: Overbroad patent claims can restrict follow-on innovation even when the disclosed information is limited.
- What they did: The work argues for patent scope reduction specifically for patents that claim more than they disclose.
- The result: Reducing such overclaiming is linked to greater room for rival innovators, not generics.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.